Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185198
Status:
COMPLETED
Last Update Posted:
2014-04-02
First Post:
2005-09-09
Brief Title:
Efficacy and Safety of Testogel in Men With Partial Androgen Deficiency of Aging Males PADAM
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Multicenter Double Blind Randomized Placebo Controlled Study of Testogel Testosterone 50-100mg to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males PADAM Over a Period of 6 Months With 12 Months Open Label Follow-up
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the effect of a testosterone replacement therapy called Testogel in men with PADAM The effects on body composition lean fat and bone and other symptoms of PADAM and safety will be studied
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG Germany
Bayer Schering Pharma AG Germany is the sponsor of the trial
Bayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 307720 | OTHER | Company internal | None |
| 2004-001545-15 | EUDRACT_NUMBER | None | None |